Fanapt

Novartis has a chance to immediately steal significant market share upon commercial launch of Fanapt, which is now due to occur early next year.

Biotech Sector and Stocks Analysis from Seeking Alpha 2009

The Rockville biotech, which around this time last year was laying off roughly 40 percent of its work force because of regulatory setbacks, has now officially given Novartis exclusive rights to sell its first drug, a schizophrenia drug called Fanapt, in the U.S. and Canada.

Jacksonville Business News - Local Jacksonville News | Jacksonville Business Journal 2009

The Rockville biotech, which around this time last year was laying off roughly 40 percent of its work force because of regulatory setbacks, has now officially given Novartis exclusive rights to sell its first drug, a schizophrenia drug called Fanapt, in the U.S. and Canada.

Jacksonville Business News - Local Jacksonville News | Jacksonville Business Journal 2009

The Rockville biotech, which around this time last year was laying off roughly 40 percent of its work force because of regulatory setbacks, has now officially given Novartis exclusive rights to sell its first drug, a schizophrenia drug called Fanapt, in the U.S. and Canada.

Los Angeles Business News - Local Los Angeles News | Los Angeles Business from bizjournals 2009

In the most profitable transaction, the Liangs allegedly traded ahead of a May 2009 announcement by Vanda Pharmaceuticals Inc. that its schizophrenia drug Fanapt had received FDA approval.

'Insider' Is Charged at FDA Alicia Mundy 2011

Mr. Liang is alleged to have traded Vanda shares in advance of the FDA's rejection of its proposed schizophrenia drug Fanapt in July 2008, and leading up to FDA approval of the drug in May 2009.

Insider-Trading Case Puts Focus on Key FDA System Alicia Mundy 2011

Outshining any other company in the market, Vanda Pharmaceuticals rose 6.76, or 626%, to 7.84, as the Food and Drug Administration approved the Rockville, Md., biopharmaceutical company's schizophrenia drug Fanapt.

Hot Topic, Blackboard Pace a Broad Decline 2009

Vanda NASDAQ: VNDA is making plans for a new headquarters at the same time it is working to expand the market for its first commercial product, the schizophrenia drug Fanapt.

unknown title 2011

Titan also has Probuphine being tested in the treatment of chronic pain and receives an 8% royalty on sales of Vanda's VNDA treatment for schizophrenia, Fanapt.

unknown title 2011

Biotoscana will seek regulatory approval for Fanapt in Argentina, and Vanda will supply the drug to the company.

unknown title 2011